S4 Table. Post-index changes in LLT patterns among all patients discharged with MI

|  | **All patients in sample** **for primary objective** **N=4,595** |
| --- | --- |
| **Post-index LLT Changes** | **N** | **%** |
| **Changes in LLT use from first Rx during 3-month pre-index period to last Rx in 1-mon post-index (n, %)** |
| **Patients with 1-month post index CE\*** | 4,425  | 100.00% |
| LLT initiation |  410  | 9.27% |
| No LLT initiation |  152  | 3.44% |
| Discontinuation |  311  | 7.03% |
| Statin Intensified |  405  | 9.15% |
| Statin Lowered |  161  | 3.64% |
| Statin to Eze Augmentation |  16  | 0.36% |
| Eze to Statin Augmentation |  1  | 0.02% |
| Statin switch to Eze |  1  | 0.02% |
| Eze switch to Statin |  1  | 0.02% |
| Statin Same |  2,961  | 66.92% |
| Eze Same |  1  | 0.02% |
| Statin drop off |  1  | 0.02% |
| Switch to PCSK9i |  1  | 0.02% |
| PCSK9i Same |  2  | 0.05% |
| PCSK9i Intensified |  1  | 0.02% |
| **Changes in LLT use from first Rx during 1-mon post-index period to last Rx in 6-mon post-index (n, %)** |
| **Patients with 6-month post index CEb** | 4,595  | 100.00% |
| LLT initiation |  184  | 4.00% |
| No LLT initiation |  325  | 7.07% |
| Discontinuation |  -  | 0.00% |
| Statin Intensified |  365  | 7.94% |
| Statin Lowered |  399  | 8.68% |
| Statin to Eze Augmentation |  62  | 1.35% |
| Eze to Statin Augmentation |  -  | 0.00% |
| Statin switch to Eze |  -  | 0.00% |
| Eze switch to Statin |  1  | 0.02% |
| Statin Same |  3,252  | 70.77% |
| Eze Same |  2  | 0.04% |
| Statin drop off |  -  | 0.00% |
| Switch to PCSK9i |  1  | 0.02% |
| PCSK9i Same |  4  | 0.09% |
| PCSK9i Intensified |  -  | 0.00% |
| **Changes in LLT use from first Rx during 1-mon post-index period to last Rx in 12-mon post-index (n, %)** |
| **Patients with 12-month post index CEc** | 4,595  | 100.00% |
| LLT initiation |  208  | 4.53% |
| No LLT initiation |  301  | 6.55% |
| Discontinuation |  -  | 0.00% |
| Statin Intensified |  356  | 7.75% |
| Statin Lowered |  485  | 10.55% |
| Statin to Eze Augmentation |  99  | 2.15% |
| Eze to Statin Augmentation |  1  | 0.02% |
| Statin switch to Eze |  -  | 0.00% |
| Eze switch to Statin |  -  | 0.00% |
| Statin Same |  3,135  | 68.23% |
| Eze Same |  2  | 0.04% |
| Statin drop off |  -  | 0.00% |
| Switch to PCSK9i |  4  | 0.09% |
| PCSK9i Same |  4  | 0.09% |
| PCSK9i Intensified |  -  | 100.00% |

EZE- ezetimibe; LLT - lipid Lowering Therapy; PCSK9i - Protein convertase subtilisin/kexin type 9 inhibitors; Rx - prescription

\*Patients with 1-month post index CE. Patients with at least one claim for any service (i.e., Drug, Procedures, consultation etc. in any market CVD or non-CVD) in 1-month post index period, these patients were selected and the change in LLT use is reported.